Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 541 to 555 of 965 results for death

  1. Cancer: bowel screening (60 to 74 years) (IND64)

    This indicator covers the proportion of eligible people aged 60 to 74 years whose record shows a bowel screening test has been performed within the last 2.5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG83

    Network / system level indicators
    Last updated
    31 October 2023

  2. Refractory extrapulmonary sarcoidosis: infliximab (ES4)

    Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making

    Evidence summary
    Published
    17 January 2017

  3. Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma in adults who have not had ipilimumab.

    Technology appraisal guidance
    Last updated
    12 September 2017
    View recommendations

    Sections for TA366

  4. Recognising dying:- What can multiprofessional teams do to reduce the impact of uncertainty of recognising when a person is entering the last days of life on clinical care, shared decision-making and communication with the dying person and those important to them?

    identification and/or achievement of patient wishes such as preferred place of death. In addition the barriers and facilitators for the...

    Research recommendation
    Published
    27 January 2016

  5. Reducing the risk of complications of anticancer treatment in children and young people, and in adults diagnosed with lymphoma:- Randomised studies should investigate primary prophylaxis of neutropenic sepsis in 2 populations: children and young people (aged under 18) having treatment for solid tumours or haematological malignancies, or stem cell transplantation; and adults (aged 18 and older) diagnosed with lymphoma. The studies should compare the effectiveness of fluoroquinolone antibiotics given alone, fluoroquinolone antibiotics given together with G-CSF preparations, and G-CSF preparations given alone. Outcome measures should include overall mortality, infectious episodes and adverse events. In addition, quality of life should be determined using quantitative and qualitative methods. The resulting data should be used to develop a cost-effectiveness analysis comparing these 3 forms of prophylaxis in children and young people having anticancer treatment, and in adults diagnosed with lymphoma.

    medication. The effects of these differences are not known, but it is known that death rates from neutropenic sepsis are higher in...

    Research recommendation
    Published
    9 June 2015

  6. Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)

    Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making

    Evidence summary
    Published
    13 March 2013

  7. Living-donor liver transplantation (IPG535)

    Evidence-based recommendations on living-donor liver transplantation. This involves replacing a diseased or damaged liver with a healthy one from a living human donor.

    Interventional procedures guidance
    Published
    25 November 2015
    View recommendations

    Sections for IPG535

  8. TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation (MIB60)

    NICE has developed a medtech innovation briefing (MIB) on the TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation

    Medtech innovation briefing
    Published
    23 March 2016

  9. Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis (TA276)

    Evidence-based recommendations on colistimethate sodium (Colobreathe) and tobramycin (TOBI Podhaler) dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis in people of 6 years and over.

    Technology appraisal guidance
    Published
    27 March 2013
    View recommendations

    Sections for TA276

  10. Designing systems for documenting drug allergy:- Which documentation strategies would be most clinically and cost effective to minimise the number of people who are re-exposed to drugs to which they have a suspected or confirmed allergy, looking in particular at: - electronic health records that include features specifically designed to record and alert clinicians to drug allergy information, compared with systems without such features and - different formats for patient-held, structured drug allergy documentation?

    the majority of people, a minority of these incidents have caused harm or death. The systematic review undertaken for this guideline...

    Research recommendation
    Published
    9 June 2015

  11. Treatment of convulsive status epilepticus (that is, not just refractory): What is the most effective and safest AED to treat: established (usually lasting longer than 30 minutes) convulsive status epilepticus refractory convulsive status epilepticus?

    complicated by irreversible neurological and intellectual sequelae, including death. Reasons for these complications include the...

    Research recommendation
    Published
    13 August 2021

  12. Pharyngeal electrical stimulation for neurogenic dysphagia (IPG781)

    Evidence-based recommendations on pharyngeal electrical stimulation for neurogenic dysphagia. This involves passing a catheter through the nose and into the throat where it is used to deliver small amounts of electrical current. The current travels from the throat to the brain and stimulates the areas involved in swallowing.

    Interventional procedures guidance
    Published
    23 January 2024
    View recommendations

    Sections for IPG781

  13. Skin involvement in systemic sclerosis: rituximab (ES7)

    Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making

    Evidence summary
    Published
    7 March 2017

  14. Entrectinib for treating NTRK fusion-positive solid tumours (TA644)

    Evidence-based recommendations on entrectinib (Rozlytrek) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children over 12 years.

    Technology appraisal guidance
    Published
    12 August 2020
    View recommendations

    Sections for TA644

  15. Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (HST31)

    Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity and hyperphagia in Bardet-Biedl syndrome in people 6 years and over, only if they are between 6 and 17 years when treatment starts.

    Highly specialised technologies guidance
    Published
    22 May 2024
    View recommendations

    Sections for HST31